<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37019065</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-1102</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Value in health regional issues</Title><ISOAbbreviation>Value Health Reg Issues</ISOAbbreviation></Journal><ArticleTitle>Cost of Illness in Patients With COVID-19 Admitted in Three Brazilian Public Hospitals.</ArticleTitle><Pagination><StartPage>34</StartPage><EndPage>43</EndPage><MedlinePgn>34-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vhri.2023.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-1099(23)00022-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The severity and transmissibility of COVID-19 justifies the&#xa0;need to identify the factors associated with its cost of illness (CoI). This study aimed to identify CoI, cost predictors, and cost drivers in the management of patients with COVID-19 from hospital and Brazil's Public Health System (SUS) perspectives.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a multicenter study that evaluated the CoI in patients diagnosed of COVID-19 who reached hospital discharge or died before being discharged between March and September 2020. Sociodemographic, clinical, and hospitalization data were collected to characterize and identify predictors of costs per patients and cost drivers per admission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1084 patients were included in the study. For hospital perspective, being overweight or obese, being between 65 and 74 years old, or being male showed an increased cost of 58.4%, 42.9%, and 42.5%, respectively. From SUS perspective, the same predictors of cost per patient increase were identified. The median cost per admission was estimated at US$359.78 and US$1385.80 for the SUS and hospital perspectives, respectively. In addition, patients who stayed between 1 and 4 days in the intensive care unit (ICU) had 60.9% higher costs than non-ICU patients; these costs significantly increased with the length of stay (LoS). The main cost driver was the ICU-LoS and COVID-19 ICU daily for hospital and SUS perspectives, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The predictors of increased cost per patient at admission identified were overweight or obesity, advanced age, and male sex, and the main cost driver identified was the ICU-LoS. Time-driven activity-based costing studies, considering outpatient, inpatient, and long COVID-19, are needed to optimize our understanding about cost of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Layssa Andrade</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Pharmaceutical Science, Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucchetta</LastName><ForeName>Rosa Camila</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, S&#xe3;o Paulo State University, Araraquara, Brazil; Sustainability and Social Responsibility, Hospital Alem&#xe3;o Oswaldo Cruz, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Ant&#xf4;nio Matoso</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinics Hospital Complex of the Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetti</LastName><ForeName>Aline de F&#xe1;tima</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Pharmaceutical Science, Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xavier</LastName><ForeName>Cecilia Silva</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, S&#xe3;o Paulo State University, Araraquara, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanches</LastName><ForeName>Andr&#xe9;ia Cristina Conegero</ForeName><Initials>ACC</Initials><AffiliationInfo><Affiliation>Center for Medical and Pharmaceutical Sciences, State University of Western Paran&#xe1;, Cascavel, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borba</LastName><ForeName>Helena Hiemisch Lobo</ForeName><Initials>HHL</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliota</LastName><ForeName>Ana Fl&#xe1;via Redolfi</ForeName><Initials>AFR</Initials><AffiliationInfo><Affiliation>Center for Medical and Pharmaceutical Sciences, State University of Western Paran&#xe1;, Cascavel, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignoli</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Assistance, Paran&#xe1; State Health Department, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastroianni</LastName><ForeName>Patr&#xed;cia de Carvalho</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, S&#xe3;o Paulo State University, Araraquara, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venson</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virtuoso</LastName><ForeName>Suzane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Medical and Pharmaceutical Sciences, State University of Western Paran&#xe1;, Cascavel, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Nadai</LastName><ForeName>Tales Rubens</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Public Health, Faculty of Dentistry of Bauru, S&#xe3;o Paulo State University, Bauru, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiens</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Federal University of Paran&#xe1;, Curitiba, Brazil. Electronic address: astrid@ufpr.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health Reg Issues</MedlineTA><NlmUniqueID>101592642</NlmUniqueID><ISSNLinking>2212-1099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050177" MajorTopicYN="N">Overweight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006779" MajorTopicYN="N">Hospitals, Public</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cost analysis</Keyword><Keyword MajorTopicYN="N">cost of illness</Keyword><Keyword MajorTopicYN="N">hospital care</Keyword><Keyword MajorTopicYN="N">hospital costs</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37019065</ArticleId><ArticleId IdType="pmc">PMC10069823</ArticleId><ArticleId IdType="doi">10.1016/j.vhri.2023.02.004</ArticleId><ArticleId IdType="pii">S2212-1099(23)00022-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19) situation reports. World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/</Citation></Reference><Reference><Citation>Inform from the Brazilian Society of Infectious Diseases (SBI) on the New Coronavirus (Updated on 03/12/2020). Brazilian Society of Infectology. www.infectologia.org.br</Citation></Reference><Reference><Citation>Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Methodological guidelines: economic evaluation guideline  Ministry of Health, Secretariat of Science, Technology and Strategic Inputs, Department of Science and Technology, Brazil. https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf</Citation></Reference><Reference><Citation>Miethke-Morais A., Cassenote A., Piva H., et al. COVID-19-related hospital cost-outcome analysis: the impact of clinical and demographic factors. Braz J Infect Dis. 2021;25(4):101609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373618</ArticleId><ArticleId IdType="pubmed">34454894</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Husereau D., Drummond M., Augustovski F., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">35031088</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for diagnosis and treatment of COVID-19  Ministry of Health, Secretariat of Science, Technology, Innovation and Strategic Inputs in Health &#x2013; SCTIE, Brazil. https://saude.rs.gov.br/upload/arquivos/202004/14140600-2-ms-diretrizes-covid-v2-9-4.pdf</Citation></Reference><Reference><Citation>Obesity. World Health Organization. https://www.who.int/health-topics/obesity#tab=tab_1</Citation></Reference><Reference><Citation>Methodological guideline: micro-costing studies applied to economic evaluations in health. Ministry of Health, Secretariat of Science, Technology and Strategic Inputs, Department of Science and Technology, Brazil. https://rebrats.saude.gov.br/images/Documentos/2022/20220419_diretrizes_microcusteio_15062021.pdf</Citation></Reference><Reference><Citation>Tan S.S. Microcosting in Economic Evaluations: Issues of Accuracy, Feasibility, Consistency and Generalisability. Optima Grafische Communicatie. https://repub.eur.nl/pub/17354/091127_Tan,%20Siok%20Swan.pdf Accessed May 7, 2022.</Citation></Reference><Reference><Citation>Quotations and bulletins: currency quotation. Central Bank of Brazil - Federal Government. https://www.bcb.gov.br/estabilidadefinanceira/historicocotacoes</Citation></Reference><Reference><Citation>Oliveira L.A., Lucchetta R., Wiens A. Cost of Illness in Patients With COVID-19 of Three Brazilian Public Hospital. Public Health Sctland. https://publichealthscotland.scot/repository/cost-of-illness-in-patients-with-covid-19-admitted-in-three-brazilian-public-hospitals/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10069823</ArticleId><ArticleId IdType="pubmed">37019065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordinance No. 245, of March 24, 2020: Includes Procedure in the Table of Procedures, Medications, Orthoses, Prostheses and Special Materials of the SUS, for Exclusive Care of Patients With a Clinical Diagnosis of COVID-19 and Changes the Inform System. Ministry of Health, Brazil. https://bvsms.saude.gov.br/bvs/saudelegis/saes/2020/prt0245_15_06_2020_rep.html</Citation></Reference><Reference><Citation>Huang Y., Lu Y., Huang Y.M., et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7521361</ArticleId><ArticleId IdType="pubmed">33002478</ArticleId></ArticleIdList></Reference><Reference><Citation>Health accounts from the perspective of international accounting: SHA account for Brazil. Ministry of Health, Brazil. Oswaldo Cruz Foundation, Institute for Applied Economic Research (IPEA) https://www.ipea.gov.br/portal/images/stories/PDFs/livros/livros/220202_livro_contas_de_saude.pdf</Citation></Reference><Reference><Citation>Etges A.P.B.S., Stefani L.P.C., Vrochides D., Nabi J., Polanczyk C.A., Urman R.D. A standardized framework for evaluating surgical enhanced recovery pathways: a recommendations statement from the TDABC in health-care consortium. J&#xa0;Heal Econ Outcomes Res. 2021;8(1):116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8225410</ArticleId><ArticleId IdType="pubmed">34222551</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvis-Zakzuk N.J., Fl&#xf3;rez-Tanus &#xc1;., D&#xed;az-Jim&#xe9;nez D., et al. How expensive are hospitalizations by COVID-19? Evidence from Colombia. Value Heal Reg Issues. 2022;31:127&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167033</ArticleId><ArticleId IdType="pubmed">35671540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchetta R.C., Lemos I.H., Santos A.C.S., et al. Poss&#xed;veis desfechos de longo prazo da Covid-19: uma revis&#xe3;o sistem&#xe1;tica de escopos. J&#xa0;Heal Biol Sci. 2021;9(1):1.</Citation></Reference><Reference><Citation>Wolter N., Jassat W., Walaza S., et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Liu Y., Tang X., He D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021;9:1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8669511</ArticleId><ArticleId IdType="pubmed">34917580</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>